A 4-week, randomized, double-masked study to evaluate efficacy of deproteinized calf blood extract eye drops versus sodium hyaluronate 0.3% eye drops in dry eye patients with ocular pain

被引:15
|
作者
Wu, Yaying [1 ]
Jin, Xiuming [1 ]
Mou, Yujie [1 ]
Yuan, Kelan [1 ]
Min, Jinjin [1 ]
Huang, Xiaodan [1 ]
机构
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Eye Ctr, 88 Jiefang Rd, Hangzhou 310009, Peoples R China
基金
中国国家自然科学基金;
关键词
Clinical trial; dry eye disease (DED); deproteinized calf blood extract eye drops; ocular pain; AUTOLOGOUS SERUM TEARS; CORNEAL NEUROPATHY; DEPRESSION; INFLAMMATION; MANAGEMENT; MECHANISMS; THERAPY; ANXIETY; DISEASE;
D O I
10.21037/apm-20-1453
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: To evaluate the clinical efficiency of the treatment of dry eye disease (DED) with ocular pain using deproteinized calf blood extract (DCBE) eye drops as compared to 0.3% sodium hyaluronate (SH) eye drops. Methods: This prospective, single-center, masked (double-blind), randomized controlled study included 53 patients divided into two groups: DCBE (n=22) and SH (n=31) group. The DCBE group received DCBE eye drops for 4 weeks, and the SH group received 0.3% SH eye drops for 4 weeks. Corneal fluorescein staining (CFS) scores, tear break up time (TBUT), Schirmer test and the ocular surface disease index (OSDI) scores were evaluated in all patients before treatment, 2 and 4 weeks post-treatment. Results: The DCBE group showed better improvement in the OSDI light sensitivity scores and ocular pain scores compared with the SH group (P<0.05). At 2 and 4 weeks post-treatment, the DCBE group and the SH group showed significant improvement in TBUT, Schirmer test, CFS, OSDI score, light sensitivity score and ocular pain score (P<0.05) compared with the data from before treatment. Conclusions: This study indicates that DCBE eye drops can relieve ocular pain and light sensitivity in dry eye patients better than SH eye drops.
引用
收藏
页码:3617 / 3625
页数:9
相关论文
共 50 条
  • [31] Comment on efficacy, safety, and tolerability of Lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease
    Srikanth, Krishnagopal
    Sridhanya, V
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2025, 73 (01) : 154 - 154
  • [32] Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial
    Cochereau, Isabelle
    Goldschmidt, Pablo
    Goepogui, Andre
    Afghani, Tayyab
    Delval, Laurent
    Pouliguen, Pascale
    Bourcier, Tristan
    Robert, Pierre-Yves
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2007, 91 (05) : 667 - 672
  • [33] Viscous carbomer eye drops in patients with dry eyes - Efficacy and safety. A randomized, open, cross-over, multicentre study
    Marner, K
    Moller, PM
    Dillon, M
    RaskPedersen, E
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 1996, 74 (03): : 249 - 252
  • [34] Prophylactic effectiveness of tobramycin-dexamethasone eye drops compared with tobramycin/vehicle eye drops in controlling post-surgical inflammation in cataract patients - Prospective, randomised, double-masked, two-arm, parallel-group, placebo-controlled, multicentre study
    Notivol, R
    Amin, D
    Whitling, A
    Wells, D
    Kennedy, M
    Cockrum, PC
    CLINICAL DRUG INVESTIGATION, 2004, 24 (09) : 523 - 533
  • [35] A Randomized, Double-Masked, Parallel- Group, Phase 2a Dry Eye Disease Clinical Trial to Evaluate the Safety and Efficacy of Topical Ocular ADX-102, a Novel Aldehyde Sequestering Agent
    Clark, David
    Ousler, George W.
    Hollander, David
    Brady, Todd
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [36] Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study
    Chen, Di
    Zhang, Shunhua
    Bian, Ailing
    Hong, Jing
    Deng, Yingping
    Zhang, Mingchang
    Chen, Wei
    Shao, Yan
    Zhao, Jialiang
    MEDICINE, 2019, 98 (31)
  • [37] Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study
    Yuichi Hori
    Koji Oka
    Maya Inai
    Advances in Therapy, 2022, 39 : 3654 - 3667
  • [38] Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study
    Hori, Yuichi
    Oka, Koji
    Inai, Maya
    ADVANCES IN THERAPY, 2022, 39 (08) : 3654 - 3667
  • [39] A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
    Tauber, Joseph
    Schechter, Barry A.
    Bacharach, Jason
    Toyos, Melissa M.
    Smyth-Medina, Robert
    Weiss, Sidney L.
    Luchs, Jodi I.
    CLINICAL OPHTHALMOLOGY, 2018, 12 : 1921 - 1929
  • [40] A double-masked, Placebo-Controlled, Phase 1b/2a Study of EXN407 Eye Drops in Patients with Mild Center Involving Diabetic Macular Edema (DME)
    Lhuillier, Loic Cm
    Mehta, Hemal
    Gilhotra, Jagjit
    Chen, Fred
    Wickremasinghe, Sanjeewa
    Heriot, Wilson
    Davies, Peter
    Ooi, Lily
    Arnold, Jennifer
    Merani, Rohan
    Taylor, Mike
    Bates, David O.
    Fraser-Bell, Samantha
    CGillies, Mark
    Fsadni, Mario G.
    Chang, Andrew
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)